 |
市场调查报告书
商品编码
1935314
皮癣菌症/甲癣治疗市场按产品类型、治疗方法、最终用户和地区划分Dermatophytic Onychomycosis Treatment Market, By Product Type, By Treatment, By End User, By Geography |
||||||
价格
简介目录
预计到 2026 年，皮癣菌甲癣治疗市场价值将达到 72.966 亿美元，预计到 2033 年将达到 122.197 亿美元，2026 年至 2033 年的年复合成长率（CAGR）为 7.6%。
| 报告覆盖范围 | 报告详情 | ||
|---|---|---|---|
| 基准年： | 2025 | 2026年市场规模： | 72.966亿美元 |
| 历史数据时期： | 2020年至2024年 | 预测期： | 2026年至2033年 |
| 预测期（2026-2033年）复合年增长率： | 7.60% | 预计2033年价值： | 122.197亿美元 |
甲癣是一种由红色毛癣菌或须癣毛癣菌引起的真菌感染疾病，有时也可能由酵母菌或霉菌引起。甲癣的主要原因是接触昆虫增多和潮湿环境，这些因素为真菌生长创造了理想的条件。甲癣的主要症状包括指甲下方出现白色或黄色斑点、指甲增厚、指甲边缘碎裂。
本次调查的主要特点
- 本报告对全球皮癣菌甲癣治疗市场进行了详细分析，以 2025 年为基准年，给出了预测期（2026-2033 年）的市场规模和復合年增长率（%）。
- 该报告还重点介绍了各个细分市场的潜在商机，并概述了该市场具有吸引力的投资提案矩阵。
- 该研究还提供了有关市场驱动因素、限制因素、机会、新产品发布或核准、市场趋势、区域展望以及主要企业采取的竞争策略的重要见解。
- 本报告根据以下参数介绍了全球皮癣菌甲癣治疗市场主要企业的概况：公司概况、财务表现、产品系列、市场地位、分销策略、主要发展、策略和未来计划。
- 本报告的研究结果将帮助负责人和经营团队就即将推出的产品、技术升级、市场扩张和行销策略做出明智的决策。
- 这份全球皮癣菌甲癣治疗市场报告的目标对象包括该行业的各类相关人员，例如投资者、供应商、产品製造商、经销商、新参与企业和金融分析师。
- 相关人员将能够透过用于分析全球皮癣菌甲癣治疗市场的各种策略矩阵轻鬆做出决策。
目录
第一章 研究目标与前提条件
- 调查目的
- 先决条件
- 简称
第二章 市场范围
- 报告概述
- 市场定义和范围
- 执行摘要
- Coherent Opportunity Map（COM）
第三章 市场动态、监理及趋势分析
- 市场动态
- 司机
- 抑制因素
- 市场机会
- 影响分析
- 市场趋势
- 重大进展
- 法规环境
- 救赎方案
- 併购趋势
- PEST分析
4. 2026-2033年全球皮癣菌甲癣治疗市场（依产品类型划分）
- 药片
- 指甲油
5. 2026-2033年全球皮癣菌症/甲癣治疗市场（依治疗方法）
- 口服
- 外用
6. 2026-2033年全球皮癣菌甲癣治疗市场（依最终用户划分）
- 医院
- 诊所
- 独立药房
- 邮购药房
- 药局
7. 2026-2033年全球皮癣菌症/甲癣治疗市场（依地区划分）
- 北美洲
- 我们
- 加拿大
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲国家
- 欧洲
- 德国
- 英国
- 法国
- 义大利
- 西班牙
- 俄罗斯
- 其他欧洲
- 亚太地区
- 中国
- 印度
- 日本
- 澳洲
- 韩国
- ASEAN
- 亚太其他地区
- 中东
- GCC
- 以色列
- 其他中东地区
- 非洲
- 南非
- 中非
- 北非
第八章 竞争情势
- 热图分析
- 市占率分析
- Valeant Pharmaceuticals International Inc.
- Galderma SA
- Novartis AG
- Pfizer Inc.
- Moberg Pharma AB
- Janssen Global Services, LLC（Johnson &Johnson Services, Inc.）
- Anacor Pharmaceuticals, Inc.
- NovaQuest Capital Management, LLC
- Novan, Inc.
第九章各节
- 参考
- 调查方法
简介目录
Product Code: CMI2053
Dermatophytic Onychomycosis Treatment Market is estimated to be valued at USD 7,296.6 Mn in 2026 and is expected to reach USD 12,219.7 Mn by 2033, growing at a compound annual growth rate (CAGR) of 7.6% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 7,296.6 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 7.60% | 2033 Value Projection: | USD 12,219.7 Mn |
Nail onychomycosis is a fungal infection is caused by a trichophyton rubrum, trichophyton mentagrophytes, and in some cases it is caused by yeasts and molds. The major factors responsible for nail onchomycosis infection is increased exposure to worm and moist environment which leads to perfect condition for fungus to grow and proliferate. The major symptoms of onychomycosis comprises of white and yellow spots under the nail leading to discoloration, nail thickening, and formation of crumbling edges on the nail.
Key features of the study
- This report provides in-depth analysis of the global dermatophytic onychomycosis treatment market and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period (2026-2033), considering 2025 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global dermatophytic onychomycosis treatment market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
- Key companies covered as a part of this study include Valeant Pharmaceuticals International Inc., Galderma S.A., Novartis AG, Pfizer Inc., Moberg Pharma AB, Janssen Global Services, LLC (Johnson & Johnson Services, Inc.), Anacor Pharmaceuticals, Inc., NovaQuest Capital Management, L.L.C., and Novan, Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
- The global dermatophytic onychomycosis treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global dermatophytic onychomycosis treatment market
Market Segmentation
- By Product Type
- Tablets
- Nail Paints
- By Treatment
- Oral
- Topical
- By End User
- Hospitals
- Clinics
- Independent Pharmacies
- Mail Order Pharmacies
- Drug Stores
- By Region
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East & Africa
- GCC Countries
- Israel
- Rest of Middle East & Africa
- Global Dermatophytic Onychomycosis Treatment Market: Competitive Landscape
- Valeant Pharmaceuticals International Inc.
- Galderma S.A.
- Novartis AG
- Pfizer Inc.
- Moberg Pharma AB
- Janssen Global Services, LLC (Johnson & Johnson Services, Inc.)
- Anacor Pharmaceuticals, Inc.
- NovaQuest Capital Management, L.L.C.
- Novan, Inc.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Product Type
- Market Snippet, By Treatment
- Market Snippet, By End User
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Regulatory Scenario
- Reimbursement Scenario
- Merger and Acquisition Scenario
- PEST Analysis
4. Global Dermatophytic Onychomycosis Treatment Market, By Product Type, 2026 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2019 and 2033 (%)
- Y-o-Y Growth Analysis, 2017 - 2033
- Segment Trends
- Tablets
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
- Nail Paints
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
5. Global Dermatophytic Onychomycosis Treatment Market, By Treatment, 2026 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2019 and 2033 (%)
- Y-o-Y Growth Analysis, 2017 - 2033
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
- Topical
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
6. Global Dermatophytic Onychomycosis Treatment Market, By End User, 2026 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2019 and 2033 (%)
- Y-o-Y Growth Analysis, 2017 - 2033
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
- Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
- Independent Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
- Mail Order Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
- Drug Stores
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
7. Global Dermatophytic Onychomycosis Treatment Market, By Region, 2026 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, By Region, 2019 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2017-2033
- North America
- Market Size and Forecast, By Product Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Treatment, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By End User, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Country, 2026 - 2033, (USD Mn)
- U.S.
- Canada
- Latin America
- Market Size and Forecast, By Product Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Treatment, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By End User, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Country, 2026 - 2033, (USD Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Market Size and Forecast, By Product Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Treatment, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By End User, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Country, 2026 - 2033, (USD Mn)
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Product Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Treatment, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By End User, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Country, 2026 - 2033, (USD Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Market Size and Forecast, By Product Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Treatment, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By End User, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Country, 2026 - 2033, (USD Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Market Size and Forecast, By Product Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Treatment, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By End User, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Country, 2026 - 2033, (USD Mn)
- South Africa
- Central Africa
- North Africa
8. Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
- Valeant Pharmaceuticals International Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Galderma S.A.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Novartis AG
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Pfizer Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Moberg Pharma AB
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Janssen Global Services, LLC (Johnson & Johnson Services, Inc.)
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Anacor Pharmaceuticals, Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- NovaQuest Capital Management, L.L.C.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Novan, Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Analyst Views
- Valeant Pharmaceuticals International Inc.
9. Section
- References
- Research Methodology
- About Us and Sales Contact
